Renalytix stock analysis
Want to see GB:RENX full AI Analyst Report?
Renalytix (RENX) Share Price & Analysis
RENX Stock Chart & Stats
- Day’s Range
- GBX 5.28 - GBX 5.60
- 52-Week Range
- GBX 1.60 - GBX 7.50
- Previous Close
- GBX 5.40
- Volume
- N/A
- Average Volume (3M)
- 803.85K
- Market Cap
- GBP 36.20M
- Enterprise Value
- GBP 13.29M
- Total Cash (Recent Filing)
- GBP 6.20M
- Total Debt (Recent Filing)
- GBP 5.80M
- Price to Earnings (P/E)
- ―
- Beta
- -0.54
- Next Earnings
- Dec 08, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
The sharp FY2026 revenue increase indicates stronger commercial traction for Renalytix’s kidney-risk diagnostics and expands the base from which operating leverage could develop. Continued adoption would improve the company’s ability to spread substantial fixed costs across a larger revenue stream.
Improving Cash Burn
The substantial reduction in operating cash burn shows progress toward more efficient operations and lowers the pace at which external financing is consumed. If maintained alongside growth, this improvement could extend funding runway and support a more durable path toward self-sustaining operations.
Lower Debt
Debt reduction improves the company’s financial profile by lowering fixed repayment obligations and potentially reducing financing pressure. Although equity remains negative, a smaller debt burden gives management greater flexibility to direct future funding toward commercialization, product development, and operating needs.
Bears Say
Negative Equity
Persistent negative equity signals a weakened capital base and limits financial flexibility, making Renalytix more dependent on continued external funding. This can constrain investment choices and leave the company less able to absorb setbacks while it works to scale its diagnostics business.
Persistent Negative Free Cash Flow
Ongoing negative free cash flow means the business is not yet funding its operations internally, despite the recent improvement in cash burn. Continued reliance on financing can dilute existing ownership or increase financial pressure, particularly if commercialization takes longer than expected.
Deep Unprofitability
The extreme gap between gross profit and operating costs shows that revenue remains far below the scale needed to support the current expense base. Even with recent growth and narrower losses, sustained operating deficits remain a major obstacle to durable profitability and cash generation.
Renalytix News
RENX FAQ
What was Renalytix’s price range in the past 12 months?
What is Renalytix’s market cap?
When is Renalytix’s upcoming earnings report date?
How were Renalytix’s earnings last quarter?
Is Renalytix overvalued?
Does Renalytix pay dividends?
What is Renalytix’s EPS estimate?
How many shares outstanding does Renalytix have?
What happened to Renalytix’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Renalytix?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Renalytix
Renalytix Plc specializes in developing cutting-edge in vitro diagnostic solutions for kidney diseases, leveraging the power of artificial intelligence. Their primary offering, KidneyIntelX, is an advanced diagnostic platform. It employs a sophisticated AI-enabled algorithm that synthesizes various data streams, such as scientifically validated blood biomarkers, inherited genetic factors, and personalized patient data extracted from electronic health record systems. The output is a unique, individualized risk score for each patient. These innovative tools serve multiple critical functions: they assist in the diagnosis and prognosis of kidney ailments, optimize clinical patient management, facilitate patient stratification for pharmaceutical clinical trials, and aid in the discovery of novel drug targets. The company has secured several pivotal license agreements. A partnership with Mount Sinai Health System grants rights for the development and commercialization of AI applications in kidney disease diagnostics. Another agreement with Joslin Diabetes Center, Inc. focuses on creating and marketing biomarker-based products for the diagnosis and prediction of kidney conditions. Furthermore, Renalytix holds a license with Kantaro Biosciences LLC for laboratory assays designed to detect SARS-CoV-2 antibodies. In a collaborative effort, Renalytix has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine. This alliance aims to implement an advanced clinical care paradigm, specifically designed to enhance kidney health and mitigate the progression of kidney disease and subsequent renal failure in high-risk patient populations. Founded in 2018, the company operated under the name Renalytix AI plc until its change to Renalytix Plc in June 2021. Its corporate headquarters are situated in New York, New York.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- James R. McCullough
- Employees
- 46
- Website
- renalytix.com
- Address
- 2 Leman Street, London, NY, E1W 9US, GB
Renalytix (RENX) Earnings & Revenues
RENX Earnings Call
Earnings Call SentimentNeutral
The earnings call highlighted significant strategic achievements, including Medicare coverage developments, inclusion in clinical guidelines, successful fundraising, and cost reduction efforts. However, there are challenges such as a decline in revenue and testing volumes, and adoption hurdles in the VA system. The sentiment is balanced, with positive long-term strategic developments countered by short-term operational challenges.
View all GB:RENX earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 5 | 9 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 5 | 0 | 7 |












